An automated system for assessing cognitive function in any environment

Proceedings of SPIE - The International Society for Optical Engineering

Volumn 5797, Issue , 2005, Pages 24-41

  Wesnes, Keith A ^a  

^a Cognitive Drug Research Ltd ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27544465111     PISSN: 0277786X     EISSN: None     Source Type: Conference Proceeding    
DOI: 10.1117/12.604372     Document Type: Conference Paper

References (215)

1. Allain H, Neuman E, Malbezin M, Salzman V, Guez D, Wesnes K, Gandon JM (1997). Bridging study of S12024 in 53 in-patients with Alzheimer's disease. Journal of the American Geriatrics Society 45: 125-126.
2. Anand R, Wesnes KA (1990). Cognition-enhancing effects of moclobemide, a reversible MAO inhibitor, in humans. In: Wurtman RJ et al. (Eds.) Advances in Neurology. Volume 51: Alzheimer's Disease. New York: Raven Press, pp. 261-268.
3. Ashurst EJ, Marshall ID, Wesnes KA (2004) Cognitive functioning in patients with primary insomnia. Journal of Psychopharmacology 18 (Suppl): A36
4. Bailie R, Christmas L, Price N, Restall J, Simpson PM, Wesnes, K (1989). Effects of temazapam premedication on cognitive recovery following alfentanil/propofol anaesthesia. British Journal of Anaesthesiology 63: 68-75.
5. Ballard C, Stephens S, Kenny RA Kalaria R, Tovee M, O'Brien J (2002). Profile of neuropsychological Deficits in Older Stroke Survivors without Dementia. Dementia and Geriatric Cognitive Disorders 16: 52-56.
6. Ballard C, Stephens S, McLaren A, Wesnes K, Kenny RA, Burton E, O'Brien J, Kalaria R (2002). Neuropsychological Deficits in Older Stroke Patients. Annals of the New York Academy of Sciences 977: 179-182.
7. Ballard CG, Aarsland D, McKeith I, O'Brien J, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen J-P, Brown R, Tovee M (2002). Fluctuations in attention: PD dementia vs. DLB with Parkinsonism. Neurology 59: 1714-1720.
8. Barker A, Jones R, Prior J, Wesnes K (1998). Scopolamine-induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers: A 6-year follow up. International Journal of Geriatric Psychiatry 13: 244-247.
9. Barker A, Jones R, Simpson P, Wesnes K (1995). Scopolamine induced cognitive impairment as a predictor of cognitive decline in healthy elderly volunteers. International Journal of Geriatric Psychiatry 10: 1059-1062.
10. Beuzen JN, Taylor N, Wesnes K, Wood A (1999). A comparison of the effects of olanzapine, haloperidol and placebo on cognitive and psychomotor functions in healthy elderly volunteers. Journal of Psychopharmacology 13: 152-158.
11. Birch B and Curran HV (1990). The differential effects of flumazenil on the psychomotor and amnesic actions of midazolam. Journal of Psychopharmacology, 4: 29-34.
12. Black K, Scholey A, Ayre GA, Wesnes KA, (1999) A computerised cognitive assessment of Multiple Sclerosis. Proceedings of the British Psychological Society 7: 119.
13. Blacker CVR, Greenwood D, Wesnes K, Wilson R, Woodward C, Howe I, Ali T (2004) Effect of Galantamine Hydrobromide in Chronic Fatigue Syndrome: a randomised controlled trial. Journal of the American Medical Association (in press)
14. Bosworth J, Jensen NO, Oliver S, Wesnes KA (1999) First cognitive effects of NS2359, a noradrenaline, dopamine & serotonin reuptake inhibitor, in volunteers. Journal of Psychopharmacology 13 (Suppl. A): A26.
15. Brooke C, Ehnhage A, Fransson B, Hägglöf B, Jonzon B, Kraft I, Wesnes K. (1998). The effects of intravenous morphine on cognitive function in healthy volunteers. Journal of Psychopharmacology 12: Supplement A, A45.
16. Burton EJ, Kenny RA, O'Brien J, Stephens S, Bradbury M, Rowan E, Kalaria R, Firbank M, Wesnes K, Ballard C (2004) White matter hyperintensities are associated with impairment of memory, attention and global cognitive performance in older stroke patients. Stroke 35: 1270-1275
17. Carter WO, Williams SA, Hilton F, Fischman A, Hargaden NJ, Jones S, Wesnes KA (1999) The effects in man of non-selective anticholinergics on deoxyglucose metabolism in the brain. Journal of Psychopharmacology 13 (Suppl. A): A28.
18. De Deyn PP, Van Baelen B, Hammond G, Schwalen S (2004) Effects of galantamine on subjective measures of attention and global improvements in patients with Alzheimer's disease. International Journal of Neuropsychopharmacology 7 (Suppl):382
19. Ebert U, Oertel R, Wesnes K, Kirch W (1998). Effects of physostigmine on scopolamine-induced changes in guantitative electroencephalogram and cognitive performance. Human Psychopharmacology 13: 199-210.
20. Ebert U, Siepmann M, Oertel R, Wesnes K, Kirch W (1998). Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration. Journal of Clinical Pharmacology 38: 720-726.
21. Edgar C, Preskorn S, Erickson M, Freison S, Werder S, Waddington G, Horsgood C (2004) A randomised, double-blind, parallel group comparison of the effects of citalopram vs sertaline on cognition in young healthy volunteers International Journal of Neuropsychopharmacology 7 (Suppl): S168
22. Ellis KA, Stough C, Vitetta L, Heinrich K, Nathan PJ (2001). An Investigation into the acutenootropic effects of Hypericum perforatum L. (St John's Wort) in healthy human volunteers. Behavioural Pharmacology 12: 173-182.
23. Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR (1995). Evaluation of cycloserine in the treatment of Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology 8: 226-30.
24. Fearn S, Hutchinson S, Riding G, Hill-Wilson G, Wesnes K, McCollum C (2003). Carotid Endarterectomy Improves Cognitive Function In-Patients with Exhausted Cerebrovascular Reserve. European Journal of Vascular and Endovascular Surgery 26: 529-536.
25. Fearn SJ, Pole R, Wesnes K, Faragher EB, Hooper TL, McCollum CN (2001). Cerebral injury during cardiopulmonary bypass: Emboli impair memory. The Journal of Thoracic and Cardiovascular Surgery 121: 1150-1160.
26. Ferguson J, Wesnes K, Schwartz G (2003). Reboxetine versus paroxetine versus placebo: Effects on cognitive functioning in depressed patients. International Clinical Psychopharmacology 18: 1-6.
27. Ferris S, Lucca U, Mohs R, Dubois B, Wesnes K, Erzigkeit H, Geldmacher D, Bodick N (1997). Objective psychometric tests in clinical trials of dementia drugs. Position paper from the International Working Group on Harmonisation of Dementia Drug Guidelines. Alzheimer's Disease and Associated Disorders 11: 34-38.
28. Forton DM, Thomas HC, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, Taylor-Robinson SD (2002). Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 35: 433-439.
29. Girdler NM, Fairbrother KJ, Lyne JP, Neave N, Scholey A, Hargaden N, Wesnes KA, Engler J, Rotherham NA (2002). A randomised crossover trial of post-operative cognitive and psychomotor recovery from benzodiazepine sedation: Effects of reversal with flumazenil over a prolonged recovery period. British Dental Journal 192: 335-339.
30. Girdler NM, Lyne JP, Wallace R, Neave N, Scholey A, Wesnes KA, Herman C (2002). A randomised, controlled trial of cognitive and psychomotor recovery from midazolam sedation following reversal with oral flumazenil. Anaesthesia 57: 868-876.
31. Goa KL, Fitton A. (1994). Velnacrine in Alzheimer's Disease: An Initial Appraisal of its Clinical Potential. CNS Drugs 1: 232-240.
32. Hanks GW (1995). Morphine sans Morpheus. Lancet 34: 652-653.
33. Hanks GW, O'Neill WM, Simpson PM, Wesnes K (1995). The cognitive and psychomotor effects of opioid analgesics II. A randomised controlled trial of single doses of morphine, lorazepam and placebo in healthy subjects. European Journal of Clinical Pharmacology 48: 455-460.
34. Hargaden NJ, Stubbs P, Dean A, Holdich T, Henson J, Wesnes KA (2001). The therapeutic implications of idiopathic cognitive function impairments in disease: a study of a large cohort of epilepsy patients. Journal of Psychopharmacology 15 (Suppl.): A51.
35. Harrington F, Saxby BK, McKeith IG, Wesnes K, Ford GA (2000). Cognitive performance in hypertensive and normotensive older subjects. Hypertension 36: 1079-1082.
36. Harrison BJ, Olver JS, Norman TR, Burrows GD, Wesnes KA, Nathan PJ (2004). Selective effects of acute serotonin and catecholamine depletion on memory in healthy women. Journal of Psychopharmacology 18: 32-40.
37. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB (2004) Absolute cognitive and mood improvements following acute doses of caffeine in habitual consumers and habitual non-consumers of caffeine. Journal of Psychopharmacology 18 (Suppl): A44
38. Haskell CF, Kennedy DO, Wesnes KA, Scholey AB (2004) Cognitive and mood effects of a Guarana (Paullinia cupana) extract containing low levels of caffeine: Comparison and interaction with Panex Ginseng. Journal of Psychopharmacology 18 (Suppl): A44
39. Hearing S, Wesnes K, Bowman C (1999). Beta-blockers and cognitive function in elderly hypertensive patients: Withdrawal and consequences of ACE inhibitor substitution. International Journal of Geriatric Psychopharmacology 2: 13-17.
40. Hendriks V, van den Brink W, Blanken P, Bosman I, van Ree J (2001). Heroin self-administration by means of 'chasing the dragon': pharmacodynamics and bioavailablity of inhaled heroin. European Neuropsychopharmacology 11: 241-252.
41. Holland RL, Wesnes K, Dietrich B (1994). Single dose human pharmacology of umespirone. European Journal of Clinical Pharmacology 46: 461-468.
42. Holland RL, Wesnes KA (1997). Alzheimer's disease and other dementias. In: O'Grady J, Joubert PH (Eds.) Handbook of Phase I/I I Clinical Drug Trials. Boca Raton: CRC Press, pp. 355-372.
43. Hunter R, Cameron S, Perks S & Wesnes K. (1997). The cognitive profile of unmedicated schizophrenic patients in relation to controls. Journal of Psychopharmacology 11 Suppl.: A74.
44. Jones RW, Wesnes KA, Kirby J (1991). Effects of NMDA modulation in scopolamine dementia. Annals of the New York Academy of Sciences 640: 241-244.
45. Jones S, Jensen NO, Oliver S, Wesnes KA (1999) Cognitive effects of single doses of ME3127, a novel anxiolytic in volunteers. Journal of Psychopharmacology 13 (Suppl. A): A27.
46. Jones S, Jensen NO, Oliver S, Wesnes KA (1999) First in man cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers. Journal of Psychopharmacology 13 (Suppl. A): A26.
47. Kastberg H, Jansen JA, Cole G, Wesnes K (1998). Tiagabine: Absence of kinetic or dynamic interactions with ethanol. Drug Metabolism and Drug Interactions 14: 259-273.
48. Keith MS, Stanislav SW, Wesnes KA (1998). Validity of a cognitive computerized assessment system in brain-injured patients. Brain Injury 12: 1037-1043.
49. Kennedy DO, Haskell CF, Wesnes KA, Scholey AB (2004) Potentiation of cognitive effects of Ginkgo biloba by complexation with phosphatidylserine. Journal of Psychopharmacology 18 (Suppl): A49
50. Kennedy DO, Scholey AB, Tildesley NTJ, Perry EK, Wesnes KA (2002). Modulation of mood and cognitive performance following acute administration of melissa officinalis (lemon balm). Pharmacology. Biochemistry and Behaviour 72: 953-964.
51. Kennedy DO, Scholey AB, Wesnes (2003) Effects of a soft drink containing glucose and caffeine on mood and cognitive performance Journal of Psychopharmacology 17 (Suppl.): A60
52. Kennedy DO, Scholey AB, Wesnes K (2002). Modulation of cognition and mood following administration of single doses of ginkgo biloba, ginseng and a ginkgo/ginseng combination to healthy young adults. Physiology & Behaviour 75:1-13.
53. Kennedy DO, Scholey AB, Wesnes KA (2000). The dose-dependent cognitive effects of acute administration of ginkgo biloba to healthy young volunteers. Psychopharmacology 151: 416-423.
54. Kennedy DO, Scholey AB, Wesnes KA (2001). Dose dependent changes in cognitive performance and mood following acute administration of ginseng to healthy young volunteers. Nutritional Neuroscience 4: 295-310.
55. Kennedy DO, Scholey AB, Wesnes KA (2001). Differential, dose dependent changes in cognitive performance following acute administration of a ginkgo biloba/panax ginseng combination to healthy young volunteers. Nutritional Neuroscience 4: 399-412.
56. Kennedy DO, Wake G, Savelev S, Tildesley NTJ, Perry EK, Wesnes KA, Scholey AB (2003). Modulation of Mood and Cognitive Performance Following Acute Administration of Single Doses of Melissa Officinalis (Lemon Balm) with Human CNS Nicotinic and Muscarinic Receptor-Binding Properties. Neuropsychopharmacology 28: 1871-1881.
57. Kitagawa H, Takenouchi T, Azuma R, Wesnes K, Kramer WG, Clody DE, Burnett A (2003). Safety, pharmacokinetics and effects on cognitive function of multiple doses of GTS-21 in healthy male volunteers. Neuropsychopharmacology 28: 912-955.
58. Kleinbloesem CH, Jaquet-Müller F, Al-Hamdan Y, Baldauf C, Gisclon L, Wesnes K, ef al. (1996). Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men. Clinical Trials and Therapeutics 59: 675-685.
59. Labadorf C, Manktelow TC, Labadorf S, Edgar CJ, Wesnes K, Petrini O (2004) The global cognitive effects of ginseng taken by healthy volunteers over a 21 day period. Journal of Psychopharmacology 18 (Suppl):
60. Legangneux E, McEwen J, Wesnes KA, Bergougnan L, Miget N, Canal M, L'Heritier C, Pinquier JL, Rosenzweig P (2000). The acute effects of amisulpride (50 mg and 200 mg) and haloperidol 2 mg on cognitive function in healthy elderly volunteers. Journal of Psychopharmacology 14: 164-171.
61. Liberman JN, Stewart WF, Wesnes K, Troncoso J (2002). Apolipoprotein E epsilon 4 and short-term recovery from predominantly mild brain injury. Neurology: 58: 1038-1044.
62. Lockton JA, Cole G, Hammersley M, Wesnes KA. (1998). Cognitive function is unaffected by remacemide at therapeutically relevant single doses. Journal of Psychopharmacology 12: Supplement A, A41.
63. Lockton JA, Wesnes KA, Yeates N, Rolan P, Diggory G. (1998). Remacemide does not affect cognitive function following multiple dosing. Journal of Psychopharmacology 12: Supplement A, A41.
64. Maher B, Stough C, Shelmerdine A, Wesnes K, Nathan P (2002). The acute effects of combined administration of Ginkgo biloba and Bacopa monniera on cognitive functions in humans. Human Psychopharmacology 17: 163-164.
65. Manktelow T, Marshall I, Thai D, Haller C, Benowitz N (2004) Preliminary results of a four way crossover study examining the effects of gamma Hydroxybutyrate (GHB) and alcohol. International Journal of Neuropsychopharmacology 7 (Suppl): S138
66. Manktelow TC, Downey LA, Wesnes KA, Edgar C, Baillie JK, Bennett YDJ, MacCormick I, Batty H (2002) The effect of high altitude and altitude sickness on the cognitive functioning of healthy young volunteers - the apex bolivia 2001 expedition Journal of Psychopharmacology 16 (Suppl.): A28
67. Marshall I, McKerchar C, Tinbergen J, Jongen P, Sindic C (2004) Cognitive deficits in patients with multiple sclerosis. International Journal of Neuropsychopharmacology 7 (Suppl):387
68. Marshall I, Wesnes K, Pincock C, Oakley N (2003) The development and validation of a wrist worn device for measuring attention in clinical trials Journal of Psychopharmacology 17 (Suppl.): A60
69. Marshall I, Wesnes KA, Pincock C (2003) Comparative profiles of caffeine and nicotine on attention, Journal of Psychopharmacology 17 (Suppl.): A64
70. Marshall ID, Wesnes KA (2004) Association of the CDR system to pencil and paper assessments of cognitive function in Alzheimer's Disease. Journal of Psychopharmacology 18 (Suppl): A52
71. Marshall ID, Wesnes KA (2004) Correlation of the CDR system factor scores to ADAS-COG. Journal of Psychopharmacology 18 (Suppl): A52
72. Mason BJ, Goodman AM, Dixon RM, Hameed MHA, Hulot T, Wesnes K, Hunter JA, Boyeson MG (2002). A pharmacokinetic and pharmacodynamic drug interaction study of acomposate and naltrexone. Neuropsychopharmacology 27: 596-606.
73. Matrenza C, Hughes JM, Kemp A, Wesnes K, Harrison BJ, Nathan PJ (2004). Simultaneous depletion of serotonin and catecholamines impairs sustained attention in healthy female subjects without affecting learning and memory. Journal of Psychopharmacology 18: 21-3.
74. McClelland GR, Wesnes K. (1995). The relationships between P300 and cognitive processing in simple and choice reaction tasks. Journal of Psychopharmacology 9 Suppl.: A39.
75. McCue P, Scholey AB, Herman C, Wesnes KA (2002). Validation of a telephone cognitive assessment test battery for use in chronic fatigue syndrome. Journal of Telemedicine and Telecare 8: 337-343.
76. McEwen J, Wesnes K, Rapeport WG, Williams S. (1995). The cognitive effects of single and multiple doses of UK 76,654, a selective M3 muscarinic antagonist in healthy volunteers. European Journal of Clinical Investigation 25, Suppl. 2: A64.
77. McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000). Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study. The Lancet 356: 2031-2036.
78. McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda J, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez O, Machado JC, O'Brien J, Playfer J, Reid W (2004) Dementia With Lewy Bodies The Lancet 3: 19 28
79. McKeith IG, Wesnes KA, Perry E, Ferrara, R. (2004) Hallucinations Predict Attentional Improvements with Rivastigmine in Dementia with Lewy Bodies. Dement Geriatr Cogn Disord: 18:94-100
80. McNamara (2002). Opioid switching from morphine to transdermal fentanyl for toxicity reduction in palliative care. Palliative Medicine 16: 425-434.
81. Mead GE, Wesnes KA, Shingler H, McCollum CN, O'Neill PA. (1997). Computerised assessment of cognitive function in acute stroke. Journal of Psychopharmacplogy 11 Suppl.: A59.
82. Moffat N, Lawson C. (1996). Computerised neuropsychological assessment after minor head injury and after carbon monoxide poisoning. Proceedings of the British Psychological Society 4: 115.
83. Mohr E, Knott V, Sampson M, Wesnes K, Herting R, Mendis T (1995). Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clinical Neuropsychopharmacology 18: 28-38.
84. Mohr E, Walker D, Randolph C, Sampson M, Mendis T (1996). The utility of clinical trial batteries in the measurement of Alzheimer's and Huntington's dementia. International Psychogeriatrics 8: 397-411.
85. Moon G, Wesnes KA, Manktelow TC (2002) Cognitive deficits in recently diagnosed untreated patients with Parkinson's disease Journal of Psychopharmacology 16 (Suppl.): A31
86. Moss M, Cook J, Wesnes K, Duckett P (2003). Aromas of rosemary and lavender essential oils differentially affect cognition and mood in healthy adults. International Journal of Neuroscience 113:15-38.
87. Moss MC, Hewitt S, Wesnes K, Goford J (2003) Modulation of cognition and mood by the aromas of ylang-ylang and peppermint essential oils Journal of Psychopharmacology 17 (Suppl.): A62
88. Moss MC, Scholey AB, Wesnes KA (1998). Oxygen administration selectively enhances cognitive performance in healthy young adults: A placebo-controlled double-blind crossover study. Psychopharmacology 138: 27-33.
89. Nathan PJ, Ricketts E, Wesnes K, Mrazek GW, Stough C (2002). The acute nootropic effects of ginkgo biloba in healthy older human subjects: a preliminary investigation. Human Psychopharmacology 17: 45-49.
90. Naylor L, Pincock C, Wesnes KA (1996). Organic solvent exposure and cognitive impairment. Journal of Psychopharmacology 10 Suppl.: A29
91. Neave N, Reid C, Scholey AB, Thompson JM, Moss M, Ayre G, Wesnes K, Girdler NM (2000). Dose-dependent effects of flumazenil on cognition, mood and cardio-respiratory physiology in healthy volunteers. British Dental Journal 189: 668-674.
92. Neave N, Scholey AB, Emmett JR, Moss M, Kennedy DO, Wesnes KA (2001). Water ingestion improves subjective alertness, but has no effect on cognitive performance in dehydrated healthy young volunteers. 37: 1-3.
93. Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes K, Pitt BMN (1995). The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? International Journal of Geriatric Psychiatry 10: 199-206.
94. O'Brien JT, Wiseman R, Burton EJ, Barber B, Wesnes K, Saxby B, Ford GA (2002). Cognitive associations of subcortical white matter lesions in older people. Annals of the New York Academy of Sciences 977: 436-444.
95. O'Brien KK, Saxby BK, Ballard C, Grace J, Harrington F, Ford G, O'Brien J, Swan A, Fairbairn A, Wesnes K, del Serotonin T, Edwardson J, Morris C, McKeith IG (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics 13: 231-239.
96. O'Neill ST, Findley LJ, Wesnes KA, Simpson PM, White L (1994) A longitudenal evaluation of cognitive change in Alzheimer's patients. Journal of Psychopharmacology 8 (Suppl).: A18.
97. O'Neill WM, Hanks GW, Simpson P, Fallon MT, Jenkins E, Wesnes K (2000). The cognitive and psychomotor effects of morphine in healthy subjects: A randomised, controlled trial of repeated (four) oral doses of dextropropoxyphene, morphine, lorazepam and placebo. Pain 85: 209-215.
98. O'Neill WM, Hanks GW, White L, Simpson PM, Wesnes K (1995). The cognitive and psychomotor effects of Opiod analgesics I. A randomised controlled trial of single doses of dextropropoxyphrene, lorazepam and placebo in healthy subjects. European Journal of Clinical Pharmacology 48: 447-453.
99. Parrott A, Garnham N, Wesnes K, Pincock C (1996). Cigarette smoking and abstinence: comparative effects upon cognitive task performance and mood state over 24 hours. Human Psychopharmacology 11: 391-400.
100. Parrott AC, Lees A, Garnham NJ, Jones M, Wesnes KA (1998). Cognitive performance in recreational users of MDMA or 'ecstasy': Evidence for memory deficits. Journal of Psychopharmacology 12: 79-83.
101. Parrott AC, Wesnes K (1987). Promethazine, scopolamine and cinnarazine: comparative time course of psychological performance effects. Psychopharmacology 92: 513-519.
102. Parry SW, McCue P, Ayre GA, Stout NR, Wesnes KA, and Kenny RA (1999) Cognition is impaired in elderly fallers with carotid sinus syndrome (CSS). Journal of Psychopharmacology 13 (Suppl. A): A29.
103. Pincock C, Davies G, Wesnes KA. (1997). The effects of training on the quality of performance on computerised cognitive tasks. Journal of Psychopharmacology 11 Suppl.: A57.
104. Pincock C, Jensen NO, Oliver S, Wesnes KA, Jones S (1999) Cognitive effects of multiple doses of ME3127, a novel anxiolytic, in volunteers. Journal of Psychopharmacology 13 (Suppl A) A27.
105. Pomara N, Willoughby LM, Hashim S, Sidtis JJ, Wesnes K, Greenblatt, Lajtha A (2004) Effects of Acute Lorazepam Administration on Aminergic Activity in Normal Elderly Subjects: Relationship to Performance Effects and Apolipoprotein Genotype. Neurochemical Research 29: 1391-1398
106. Pomara N, Willoughby LM, Wesnes K, Sidtis JJ (2004). Increased Anticholinergic Challenge-Induced Memory Impairment Associated with the APOE-e4 Allele in the Elderly: A Controlled Pilot Study. Neuropsychopharmacology 29: 403-409.
107. Preece AW, Iwi G, Davies-Smith A, Wesnes K, Butler S, Lim E, Varey A (1999). Effect of a 915-MHz simulated mobile phone signal on cognitive function in man. International Journal of Radiation Biology 75: 447-456.
108. Preece AW, Wesnes KA, Iwi G (1998). The effect of a 50Hz magnetic field on cognitive function in humans. International Journal of Radiation Biology 74: 463-470.
109. Rapeport WG, Muirhead DC, Williams SA, Cross M, Wesnes K (1996). Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. Journal of Clinical Psychiatry 57: 24-28.
110. Rapeport WG, Williams SA, Muirhead DC, Dewland PM, Tanner T, Wesnes K (1996). Absence of a sertraline mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. Journal of Clinical Psychiatry 57: 20-23.
111. Ritchie KA, Macdonald E, Hammersley R, O'Neil JM, McGowan DA, Dale IM, Wesnes K (1995). A pilot study of the effect of low level exposure to mercury on the health of dental surgeons. Occupational and Environmental Medicine 52: 813-817.
112. Roberts N, Pincock C, Wesnes KA. (1997). Some cognitive effects of hyperthyroidism. Journal of Psychopharmacology 11 Suppl.: A61.
113. Robinson R, Stanton J, Wiseman W, Simpson J, Wesnes K, Dewes I and VandenBurg M (1991). Computerised cognitive testing of cardiovascular patients. Biological Psychiatry 29: 482S.
114. Rodgers J, Morse R, Verrill M, Kendell K, Wesnes K, Marshall I, Manktelow TC (2003) Cognitive functioning in women following adjuvant treatment for breast cancer Journal of Psychopharmacology 17 (Suppl.): A68
115. Rowan EN, Saxby BK, Askey KA, Thomas AJ, Monktelow TC, Wesnes KA, McKeith IG (2004) Improved attentional performance in DLB and PDD following donepezil treatment. Journal of Psychopharmacology 18 (Suppl): A51
116. Russell-Duff K, Jensen NO, Mooney P, Wesnes KA. (1999) Cognitive effects of NS2389, a serotonin reuptake inhibitor, in healthy volunteers. Journal of Psychopharmacology 13 (Suppl. A): A27.
117. Ruwe FJL, Smulders RA, Kleijn HJ, Hartmans HLA, Sitsen JMA (2001). Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects. Human Psychopharmacology Clinical and Experimental 16: 449-459.
118. Saxby BK, Harrington F, McKeith I, Wesnes K, Ford GA (2003). Effects of Hypertension on Attention, Memory and Executive Function in Older Adults. Health Psychology 22: 587-591.
119. Scholey A, Mackay I, McCue P, Moss M, Chalfont L, Wesnes KA. (1998). Reversal of cognitive deficits associated with chronic fatigue syndrome by oxygen administration. Journal of Psychopharmacology 12: Supplement A, A42.
120. Scholey AB, Moss MC, Neave N, Wesnes K (1999). Cognitive performance, hyperoxia and heart rate following oxygen administration in healthy young adults. Physiology and Behaviour 67: 783-789.
121. Scholey AB, Moss MC, Wesnes KA (1998). Oxygen and cognitive performance: the temporal relationship between hyperoxia and enhanced memory. Psychopharmacology 140: 123-126.
122. Seed JA, McCue PM, Wesnes KA, Dahabra S, Young AH (2002). Basal activity of the HPA axis and cognitive function in anorexia nervosa. International Journal of Neuropsychopharmacology 5: 17-25.
123. Semos ML, Fitzpatrick K, Jones RW, Mann JB, Ramezani E, Wesnes KA. (1998). Absence of interaction between SB202026 and alcohol in healthy elderly volunteers. Journal of Psychopharmacology 12: Supplement A, A40.
124. Siegfried K (1991). First clinical impressions with an ACTH analogue (HOE 427) in the treatment of Alzheimer's disease. Annals of the New York Academy of Sciences 640: 260-283.
125. Siegfried KR (1993). Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand Suppl. 149: 26-28.
126. Siegfried KR (1993). The pharmacodynamics of velnacrine: Results and conclusions from clinical studies in healthy subjects and patients with Alzheimer's disease. In: Wilcock GK (Ed) The Management of Alzheimer's Disease. Wrightson Biomedical Publishing, 189-201.
127. Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK (1991). The Cognitive Drug Research computerised assessment system for demented patients: A validation study. International Journal of Geriatric Psychiatry 6: 95-102.
128. Simpson PM, Wesnes KA and Christmas L (1989). A computerised system for the assessment of drug-induced performance changes in young elderly or demented populations. British Journal of Clinical Pharmacology 27: 711P-712P.
129. Sitsen JMA, Maris FA, Timmer CJ (2001). Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. European Journal of Drug Metabolism and Pharmacokinetics 26: 109-121.
130. Sitsen JMA, Voortman G, Timmer CJ (2000). Pharmacokinetics of mirtazapine and lithium in healthy male subjects. Journal of Psychopharmacology 14: 172-176.
131. Sunram-Lea SI, Birchall RJ, Wesnes KA (2003) Acute administration of ginseng improves speed of attention in healthy young volunteers Journal of Psychopharmacology 17 (Suppl.): A63
132. Takkenberg J, Oudenaarde I, van der Velden E, Chalfont L, Wesnes K, van Herwerden L. (1999) Neuropsychologic dysfunction after CABG: standard cardiopulmonary bypass versus MICAB. Journal of Psychopharmacology 13 (Suppl. A): A56.
133. Taubel J, Arezina R, Hargaden N, Hargaden N, Ward T, Wesnes KA (2000) A comparison of the effects in cognitive function of E-5842 administered as a single or multiple dose. Journal of Psychopharmacology 14 (Suppl. A): A44.
134. Templeton L, Barker A, Wesnes K, Wilkinson D (1999). A double-blind, placebo-controlled trial of intravenous flumazenil in Alzheimer's disease. Human Psychopharmacology 14: 239-245.
135. Tesch, H., C. Gisselbrecht, et al. (2004). Evaluation of the cognitive effects of once weekly epoetin alfa in anemic patients with hematologic cancers receiving chemotherapy: preliminary results of the EPOLYM trial. Hematol J 5(suppl 2): S177.
136. Thompson JM, Neave N, Moss MC, Scholey A, Wesnes K, Girdler NM (1999). Cognitive properties of sedation agents: Comparison of the effects of nitrous oxide and midazolam on memory and mood. British Dental Journal 187: 557-562.
137. Tildesley NTJ, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, Scholey AB (2003). Salvia Lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacology, biochemistry and behaviour 75: 669-674.
138. Van Harten J, Stevens LA, Raghoebar M, Holland RL, Wesnes K, Cournot A (1992). Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function. Clinical Pharmacology and Therapeutics 52: 427-435.
139. van Harten J, Wesnes K, Strobel W. (1996). No kinetic or dynamic interaction between flesinoxan and fluoxetine. European Neuropsychopharmacology 6 Suppl. 3.: 40
140. Walker LG, Walker MB, Heys SD, Lolley J, Wesnes KA, Eremin O (1997). The psychological and psychiatric effects of rlL-2: A controlled clinical trial. Psycho-Oncology 6: 290-301.
141. Walker LG, Walker MG, marshall ID, Manktelow TC, Wesnes KA, Heys SD, Sarkar, TK, Hutcheon AW, Eremin O, Simpson E, Knaggs A (2002) Cognitive Function in breast cancer patients compared with age matched healthy controls Journal of Psychopharmacology 16 (Suppl.): A27
142. Walker LG, Wesnes KA, Heys SD, Walker MB, Lolley J, Eremin O (1996). The cognitive effects of recombinant lnterleukin-2 (rlL-2) therapy: A controlled clinical trial using computerised assessments. European Journal of Cancer 32A: 2275-2283.
143. Walker MP, Ayre GA, Ashton CH, Marsh VR, Wesnes K, Perry EK, O'Brien JT, McKeith IG, Ballard CG (1999). A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias. Human Psychopharmacology Clinical and Experimental 14: 483-489.
144. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG (2000). Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease and vascular dementia. Neurology 54: 1616-1625.
145. Walker MP, Ayre GA, Cummings JL, Wesnes K, McKeith IG, O'Brien JT, Ballard CG (2000). The clinician assessment of fluctuation and the one day fluctuation assessment scale. The British Journal of Psychiatry 177: 252-256.
146. Walker MP, Ayre GA, Perry EK, Wesnes K, McKeith IG, Tovee M, Edwardson JA, Ballard CG (2000). Quantification and characterisation of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 11: 327-335.
147. Wesnes K (2001). The role of attention deficits in the cognitive pathology of dementia. Alzheimer Insights 7: 1-4.
148. Wesnes K (2003). The Cognitive Drug Research computerised assessment system: Application to clinical trials. (Eds.) De Deyn P, Thiery E, D'Hooge R. Memory: Basic Concepts. Disorders and Treatment. Uitgeverij Acco: Leuven, pp. 453-472.
149. Wesnes K, Anand R, Lorscheid T (1990). Potential of moclobemide to improve cerebral insufficiency identified using a scopolamine model of ageing and dementia. Acta Psychiatrics Scandinavia Supplementum 360: 71-72.
150. Wesnes K, Anand R, Simpson PM, Christmas L (1990). The use of a scopolamine model to study the potential nootropic effects of aniracetam and piracetam in healthy volunteers. Journal of Psychopharmacology 4: 219-232.
151. Wesnes K, de Koning P, Dietrich B. (1995). A comparison of the cognitive effects of DU29894, sulpiride, haloperidol and a selective 5HT1A agonist in normal volunteers. European Journal of Clinical Investigation 25, Suppl. 2: A64.
152. Wesnes K, Faleni RA, Hefting NR, Hoogsteen G, Houben JJG, Jenkins E, Jonkman JHJ, Leonard J, Petrini O, Van Lier JJ (1997). The cognitive, subjective and physical effects of a ginkgo biloba/ panax ginseng combination in healthy volunteers with neurasthenic complaints. Psychopharmacology Bulletin 33: 677-683.
153. Wesnes K, Ferguson J, Petrini O (2004) The memory enhancing effects of gingko biloba in healthy middle-aged volunteers International Journal of Neuropsychopharmacology 7 (Suppl): 271
154. Wesnes K, Gudgeon A. (1995). A comparison of the profiles of cognitive impairment produced by alcohol, scopolamine and lorazepam. Journal of Psychopharmacology 9 Suppl.:A13.
155. Wesnes K, Harrison J (2003). The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues in Clinical Neuroscience: Dementia 5: 77-88.
156. Wesnes K, Jones RW, Kirby J (1991). The effects of D-cycloserine, a glycine agonist, in a human model of the cognitive deficits associated with ageing and dementia. British Journal of Clinical Pharmacology 31: 577-578.
157. Wesnes K, Lipton R, Kolodner K, Edgar C (2004) Darifenacin, an M3 selective receptor antagonist for the treatment of overactive bladder, does not affect cognitive function in elderly volunteers European Urology 3 (Suppl): 131
158. Wesnes K, Lockten A, Rolan P, Stephenson N, Pincock C. (1997). Volunteer study of the potential interaction between remacemide 300 mg and alcohol (0.7 g/kg). Journal of Psychopharmacology 11 Suppl.: A59.
159. Wesnes K, Luthringer R, Ambrosetti C, Edgar, Petrini O (2003). The effects of a combination of panax ginseng, vitamins and minerals on mental performance, mood and physical fatigue in nurses working night shifts: A double blind, placebo-controlled trial. Current Topics in Nutraceutical Research 1: 169-174.
160. Wesnes K, McClelland G. (1996). Acute effects of cilazapril and atenolol on cognitive function and EEG in volunteers. Journal of Psychopharmacology 10 Suppl.: A51
161. Wesnes K, McEwen J, Pritchard G. (1994). The dose and time dependent profile of cognitive impairments of alcohol in young volunteers. Journal of Clinical Pharmacology 34: 1021
162. Wesnes K, Parrott A (1992). Smoking, nicotine and human performance. In Smith A, Jones D (Eds.) Handbook of Human Performance: Volume 2. London: Academic Press, pp. 127-167.
163. Wesnes K, Pincock C (2002). Practice effects on cognitive tasks: a major problem? The Lancet Neurology 1: 473.
164. Wesnes K, Pincock C, Richardson D, Helm G, Hails S (2003). Breakfast reduces declines in attention and memory over the morning in school children. Appetite 41: 329-331.
165. Wesnes K, Scott M, Boyle M, Surmon D, Wilcock G (1993) Use of the cognitive drug research computerised assessment system to assess the efficacy of THA and galantamine Alzheimers Disease Psychopharmacology Bulletin 30: 139
166. Wesnes K, Simmons D, Rook M, Simpson PM (1987). A double blind placebo controlled trial of tanakan in the treatment of idiopathic cognitive impairment in the elderly. Human Psychopharmacology 2: 159-169.
167. Wesnes K, Simpson P, Christmas L (1990) Effects of HP 029 in a scopolamine model of ageing and dementia. International Journal of Neuropsychopharmacology 11.
168. Wesnes K, Simpson P, White L and Pinker S (1992). The Cognitive Drug Research Computerised Assessment Systems for elderly, AAMI and Demented Patients. Journal of Psychopharmacology 6: 108.
169. Wesnes K, Simpson P, White L, Pinker S. (1992) The utility, validity and predictability of the scopolamine model of dementia. International Clinical Neuropharmacology 15: Suppl. 1, Part B, 562.
170. Wesnes K, Simpson PM (1988). Can scopolamine produce a model of the memory deficits seen in ageing and dementia? In: Gruneberg MM, Morris PE, Sykes RN (Eds.) Practical Aspects of Memory: Current Research and Issues. Volume 2: Clinical and Educational Implications. Chichester: Wiley, pp. 236-242.
171. Wesnes K, Simpson PM, Christmas L (1987). The assessment of human information processing abilities in psychopharmacology. In: Hindmarch I, Stonier PD (Eds.) Human Psychopharmacology: Measures and Methods 1: 79-92.
172. Wesnes K, Simpson PM, Christmas L (1988). Puff by puff profiles of performance, mood and acceptability in low and non-low tar smokers. In: Rand MJ, Thurau K (Eds.) The Pharmacology of Nicotine. Oxford: IRL Press, pp. 406-408.
173. Wesnes K, Simpson PM, Christmas L, Anand R, McClelland GR (1989). The effects of moclobemide on cognition. Journal of Neural Transmission 28: 91-102.
174. Wesnes K, Simpson PM, Christmas L, McClelland GR, Joiner IM (1989). Acute cognitive effects of moclobemide and trazodone alone and in combination with alcohol in the elderly. British Journal of Clinical Pharmacology 27: 647-648.
175. Wesnes K, Simpson PM, Jansson B, Grahnén A, Weimann HJ, Küppers H (1997). Moxonidine and cognitive function: Interactions with moclobemide and lorazepam. European Journal of Clinical Pharmacology 52: 351-358.
176. Wesnes K, Simpson PM, Kidd A (1987). The use of a scopolamine model to study the nootropic effects of tenilsetam (CAS 997) in man. Medical Science Research 15: 1063-1064.
177. Wesnes K, Simpson PM, Kidd AG (1988). An investigation of the range of cognitive impairments induced by scopolamine 0.6 mg.s.c. Human Psychopharmacology 3: 27-41.
178. Wesnes K, Simpson PM, White L, Pinker S, Jertz G, Murphy M, Siegfried K (1991). Cholinesterase inhibition in the scopolamine model of dementia. Annals of the New York Academy of Sciences 640: 268-271.
179. Wesnes K, Strobel W. (1996). Flesinoxan improves cognition in the elderly. European Neuropsychopharmacology 6 Suppl 3.: 186.
180. Wesnes K, Zangara A, Trianes Torres MV, Maldonado EF, Ambrosetti L, Goford J (2004) Cognitive effects of stress in Andalucian children aged 8 to 12 years. Journal of Psychopharmacology 18 (Suppl): A44
181. Wesnes KA (2000). Predicting, assessing, differentiating and treating the dementias: Experience in MCI and various dementias using the CDR computerised cognitive assessment system. In: Vellas B, Fitten LJ (Eds.) Research and Practice in Alzheimer's Disease: Volume 3. Paris: Serdi, pp. 59-65.
182. Wesnes KA (2001). The use of cognitive tests to facilitate drug and dose selection Phase I and to optimise dosing in Phase IV. International Congress Series 1220: 35-50.
183. Wesnes KA, Bullock R (2001). The emerging importance of attention and the speed of cognitive function in ageing and dementia research. CPD Bulletin Old Age Psychiatry 3:11-15.
184. Wesnes KA, Garratt C, Wickens M, Gudgeon A, Oliver S (2000). Effects of sibutramine alone and with alcohol on cognitive function in healthy volunteers. British Journal of Clinical Pharmacology 49: 110-117.
185. Wesnes KA, Hildebrand K, Mohr E (1999). Computerised cognitive assessment. In: Wilcock GW, Bucks RS, Rocked K (Eds.) Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. Oxford: Oxford University Press, pp.124-136.
186. Wesnes KA, Macher J-P (2004) Modafinil reverses the marked attentional deficits produced by acute sleep deprivation in healthy volunteers. Journal of Psychopharmacology 18 (Suppl): A48
187. Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R (2001). Effects of rivastigmine on cognitive function in dementia with Lewy bodies: A randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dementia and Geriatric Cognitive Disorders 13: 183-192.
188. Wesnes KA, Meulenberg O, Vermeij B, Gulati-Chada P, Holt P, Knott V, Simpson P, Volkerts E (1996). The acute cognitive effects of amitriptyline, hydroxyzine and lorazepam in volunteers. Journal of Psychopharmacology 10 Suppl.: A51
189. Wesnes KA, Molloy S, McKeith IG, Burn D (2004) The effects of L-DOPA on attention in Parkinson's Disease and Parkinson's dementia patients. Journal of Psychopharmacology 18 (Suppl): A51
190. Wesnes KA, O'Neill ST. (1996). Benzodiazepines affect simple not choice reaction time in a choice reaction time task. Journal of Psychopharmacology 10 Suppl.: A52
191. Wesnes KA, Pincock C (1994) Comparing the cognitive profiles of multi-infarct dementia to alzheimers disease. Journal of Psychopharmacology 8 (Suppl).: A21.
192. Wesnes KA, Pincock C (1994) The cognitive profile of ageing. Journal of Psychopharmacology 8:A21.
193. Wesnes KA, Preskorn SH, Friesen S, Edgar CJ, Mikkelson BO (2002) NS2330 enhances cognitive function in elderly volunteers with possible Alzheimers Disease. Journal of Psychopharmacology 16 (Suppl.): A29
194. Wesnes KA, Ramezani E, Oliver S. (1997). FK960 antagonises the memory impairments produced by scopolamine in healthy volunteers. Journal of Psychopharmacology 11 Suppl.: A57.
195. Wesnes KA, Scott M, Morrison S, Greenwood D, Russell-Duff K, Wilcock GK. (1998). The effects of galanthamine on attention in Alzheimer's disease. Journal of Psychopharmacology 12: Supplement A, A64.
196. Wesnes KA, Simpson PM (1994) The construct validity of the cognitive drug research computerised assessment system. Journal of Psychopharmacology 8 (Suppl).: A20.
197. Wesnes KA, Simpson PM, Thompson S (1994) Cognition enhancement with physostigmine in young volunteers Journal of Psychopharmacology 8 (Suppl).: A19.
198. Wesnes KA, Simpson PM, White L (1994) The cognitive effects of moclobemide and nortriptyline in eldery depressed patients. Journal of Psychopharmacology 8 (Suppl).: A20.
199. Wesnes KA, Snorrason E, Valsson A, Bragee B, Greenwood D (2001). The cognitive effects of galanthamine in patients suffering from fibromyalgia. Journal of Psychopharmacology 15 (Suppl.): A58.
200. Wesnes KA, Walker MB, Walker LG, Heys SD, White L, Warren R, Eremin O (1997). Cognitive performance and mood after a weekend on call in a surgical unit. British Journal of Surgery 84: 493-495.
201. Wesnes KA, Ward T, McGinty A, Petrini O (2000). The memory enhancing effects of a ginkgo biloba/ panax ginseng combination in healthy middle aged volunteers. Psychopharmacology 152: 353-361.
202. Wesnes K, Neuman E, de Wilde HJG, Malbezin M, Castagné I, Crijns HJMJ, Jonkman JHG, Guez D. (1994). Pharmacodynamic effects of a repeated oral administration of 4 dose levels of S 12024-2 in 36 elderly volunteers. Neurobiology of Aging 15: S100
203. Wesnes KA, White, L, Simpson P, Herting R, Schwartz P (1994) Further evaluations of the criterion validity of the CDR computerised assessment system Journal of Psychopharmacology 8 (Suppl).: A21
204. Wesnes KA, Zangara A, Scholey A, Kennedy D (2004). Natural products as cognition enhancing agents. In J.J. Buccafusco (Ed). Cognition Enhancing Drugs, Birkhauser Verlag: Basel 151-178.
205. Wilcox C, Wesnes K, Heiser J, Simpson P, Katz B, Happy J. (1996). A double blind, eight way crossover comparison of Abercarnil, lorazepam and placebo alone and after a single dose of alcohol, on psychometric performance in healthy volunteers. Psychopharmacology Bulletin 32: 536.
206. Wilkinson L, Scholey A, Wesnes K (2002). Chewing gum selectively improves aspects of memory in healthy volunteers. Appetite 38: 1-2.
207. Williams SA, Wesnes K, Oliver SD, Rapeport WG (1996). Absence of effect of sertraline on time based sensitization of cognitive impairment with haloperidol. Journal of Clinical Psychiatry 57: 7-11.
208. Wills K, Jensen NO, Oliver S, Wesnes KA (1999) Cognitive effects of NS2330, a novel monoamine reuptake inhibitor, in volunteers. Journal of Psychopharmacology 13 (Suppl. A): A27.
209. Woodruff-Pak DS, Jaegar ME, Golman C, Wesnes KA (1999). Relationships among age, conditioned-stimulus unconditioned stimulus interval, and neuropsychological test performance. Neuropsychology 13: 90-102.
210. Zaffalon M, Wesnes K, Petrini O (2001). Credal classification for dementia screening (Eds.) Quaglini, S., Barahona P., Andreassen, S. AIME '01: Proceedings of the Eighth European Conference on Artificial Intelligence in Medicine. Lecture Notes in Computer Science, Springer-Verlag, pp. 67-76.
211. Zaffalon M, Wesnes K, Petrini O (2003). Reliable diagnosis of dementia by the naïve credal classifier inferred from incomplete cognitive data. Artificial Intelligence in Medicine 29: 61-79.
212. Zangara A (2003). Huperzine A: An alkaloid with nootropic and neuroprotective properties. Current Topics in Nutraceutical Research 1: 193-204.
213. Zangara A, Edgar C, Wesnes K, Scalfaro P, Porchet HC (2004) The effectiveness of ZT-1 and donepezil in reversing scopolamine-induced cognitive impairment in elderly volunteers International Journal of Neuropsychopharmacology 7 (Suppl): 377
214. Zhang K, Mayleben D, Roth A, Corser B, Nandy P, Harris S, Perhach J (2004) Dose and time dependent discrimination of daytime sleepiness measured by multiple sleep latency tests (MSLT), Psychomotor performance tests (PPT) and Standford Sleepiness Scale (SSS) after a single AM administration of a sedative hypnotic drug Sleep 27: A49.
215. Emre M, Aarsland D et al (2004). Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 351: 2509-2518.